ArticleJournal of translational medicine2026
Interaction between p-AMPK and RIPK3 reveals a mechanism by which AdipoAI suppresses necroptosis to attenuate periodontitis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecroptosis is implicated in the pathogenesis of various inflammatory diseases, including periodontitis. This study aimed to investigate the molecular mechanisms underlying necroptosis in gingival fibroblasts (GFs) and to evaluate the therapeutic potential of AdipoAI, a novel adiponectin receptor agonist, administered locally, along with its regulatory effect on necroptosis.
methodsAnalysis of single-cell RNA sequencing data using the AUCell scoring system demonstrated significant activation of necroptosis in human periodontal tissues, with GFs identified as the primary cellular target. Integrated approaches, including molecular docking, co-immunoprecipitation, and immunofluorescence, revealed a physical association between phosphorylated AMP-activated protein kinase (p-AMPK) and Receptor-Interacting Protein Kinase 3 (RIPK3). Additionally, we established a mouse model of experimental periodontitis and an LPS/AZD'5582/z-VAD-fmk (LAZ)-induced necroptosis model in hGFs. Techniques including Western blotting, flow cytometry, and transmission electron microscopy were employed to evaluate the effects of AdipoAI administration.
resultsLocal administration of AdipoAI significantly alleviated gingival inflammation and alveolar bone resorption in mice. In hGFs, AdipoAI effectively suppressed the activation of p-RIPK3 and phosphorylated Mixed Lineage Kinase Domain-Like protein (p-MLKL) and reduced the production of inflammatory factors. Mechanistic investigations revealed that AdipoAI binds to Adiponectin Receptor 1 (AdipoR1) - adiponectin receptor interacting protein (APPL1) to activate the AMPK signaling pathway, facilitating the association between p-AMPK and RIPK3, thereby inhibiting RIPK3/MLKL-mediated necroptosis.
conclusionsThis study is the first to unveil a mechanism by which AdipoAI suppresses GF necroptosis through p-AMPK-mediated RIPK3 regulation, offering new strategic insights and experimental evidence for targeted periodontitis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.